Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy

Maria Jose Miguez-Burbano, Ximena Burbano, David Ashkin, Arthur Pitchenik, Allan E Rodriguez, Luisamaria Pineda, Noaris Rodriguez, Gail Shor-Posner

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

The increased risk of developing lung diseases in cigarette smokers has been well recognized. The association between smoking and the risk of developing pulmonary infections in HIV-1-infected patients, however, which has not been established, was evaluated in the present study. Twenty-seven cases with lower respiratory infections (15 Pneumocystis carinii pneumonia (PCP), 12 TB cases) were compared with 27 age, gender, socio-economic and HIV status-matched patients, without history of respiratory diseases. Medical history and physical examinations were obtained every 6 months. Blood was drawn for CD4 and viral load measurements. A substantial number of HIV+ smokers who developed PCP (one-third) had been on highly active retroviral therapy (HAART) for more than 6 months and prophylaxis had been discontinued. Multivariate analyses indicated that in HIV-infected people, after controlling for HIV status and antiretrovirals, cigarette smoking doubled the risk for developing PCP (p = 0.01). Multivariate analyses demonstrated that long-term smoking also increased the risk (2 x) of developing tuberculosis (p = 0.04). Moreover, daily tobacco use seemed to attenuate by 40% the immune and virological response to antiretroviral therapies. These findings indicate that tobacco use significantly increases the risk of pulmonary diseases in HIV infected subjects and has a potential deleterious impact on antiretroviral treatment.

Original languageEnglish
Pages (from-to)39-43
Number of pages5
JournalAddiction Biology
Volume8
Issue number1
DOIs
StatePublished - Mar 1 2003

Fingerprint

Opportunistic Infections
Tobacco Use
Respiratory Tract Infections
HIV
Pneumocystis Pneumonia
Smoking
Lung Diseases
Multivariate Analysis
Therapeutics
Highly Active Antiretroviral Therapy
Viral Load
Tobacco Products
Physical Examination
HIV-1
Tuberculosis
Economics
Lung
Infection

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. / Miguez-Burbano, Maria Jose; Burbano, Ximena; Ashkin, David; Pitchenik, Arthur; Rodriguez, Allan E; Pineda, Luisamaria; Rodriguez, Noaris; Shor-Posner, Gail.

In: Addiction Biology, Vol. 8, No. 1, 01.03.2003, p. 39-43.

Research output: Contribution to journalArticle

Miguez-Burbano, Maria Jose ; Burbano, Ximena ; Ashkin, David ; Pitchenik, Arthur ; Rodriguez, Allan E ; Pineda, Luisamaria ; Rodriguez, Noaris ; Shor-Posner, Gail. / Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. In: Addiction Biology. 2003 ; Vol. 8, No. 1. pp. 39-43.
@article{8a24188645b04513983216ea7ffcfd23,
title = "Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy",
abstract = "The increased risk of developing lung diseases in cigarette smokers has been well recognized. The association between smoking and the risk of developing pulmonary infections in HIV-1-infected patients, however, which has not been established, was evaluated in the present study. Twenty-seven cases with lower respiratory infections (15 Pneumocystis carinii pneumonia (PCP), 12 TB cases) were compared with 27 age, gender, socio-economic and HIV status-matched patients, without history of respiratory diseases. Medical history and physical examinations were obtained every 6 months. Blood was drawn for CD4 and viral load measurements. A substantial number of HIV+ smokers who developed PCP (one-third) had been on highly active retroviral therapy (HAART) for more than 6 months and prophylaxis had been discontinued. Multivariate analyses indicated that in HIV-infected people, after controlling for HIV status and antiretrovirals, cigarette smoking doubled the risk for developing PCP (p = 0.01). Multivariate analyses demonstrated that long-term smoking also increased the risk (2 x) of developing tuberculosis (p = 0.04). Moreover, daily tobacco use seemed to attenuate by 40{\%} the immune and virological response to antiretroviral therapies. These findings indicate that tobacco use significantly increases the risk of pulmonary diseases in HIV infected subjects and has a potential deleterious impact on antiretroviral treatment.",
author = "Miguez-Burbano, {Maria Jose} and Ximena Burbano and David Ashkin and Arthur Pitchenik and Rodriguez, {Allan E} and Luisamaria Pineda and Noaris Rodriguez and Gail Shor-Posner",
year = "2003",
month = "3",
day = "1",
doi = "10.1080/1355621031000069864",
language = "English",
volume = "8",
pages = "39--43",
journal = "Addiction Biology",
issn = "1355-6215",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy

AU - Miguez-Burbano, Maria Jose

AU - Burbano, Ximena

AU - Ashkin, David

AU - Pitchenik, Arthur

AU - Rodriguez, Allan E

AU - Pineda, Luisamaria

AU - Rodriguez, Noaris

AU - Shor-Posner, Gail

PY - 2003/3/1

Y1 - 2003/3/1

N2 - The increased risk of developing lung diseases in cigarette smokers has been well recognized. The association between smoking and the risk of developing pulmonary infections in HIV-1-infected patients, however, which has not been established, was evaluated in the present study. Twenty-seven cases with lower respiratory infections (15 Pneumocystis carinii pneumonia (PCP), 12 TB cases) were compared with 27 age, gender, socio-economic and HIV status-matched patients, without history of respiratory diseases. Medical history and physical examinations were obtained every 6 months. Blood was drawn for CD4 and viral load measurements. A substantial number of HIV+ smokers who developed PCP (one-third) had been on highly active retroviral therapy (HAART) for more than 6 months and prophylaxis had been discontinued. Multivariate analyses indicated that in HIV-infected people, after controlling for HIV status and antiretrovirals, cigarette smoking doubled the risk for developing PCP (p = 0.01). Multivariate analyses demonstrated that long-term smoking also increased the risk (2 x) of developing tuberculosis (p = 0.04). Moreover, daily tobacco use seemed to attenuate by 40% the immune and virological response to antiretroviral therapies. These findings indicate that tobacco use significantly increases the risk of pulmonary diseases in HIV infected subjects and has a potential deleterious impact on antiretroviral treatment.

AB - The increased risk of developing lung diseases in cigarette smokers has been well recognized. The association between smoking and the risk of developing pulmonary infections in HIV-1-infected patients, however, which has not been established, was evaluated in the present study. Twenty-seven cases with lower respiratory infections (15 Pneumocystis carinii pneumonia (PCP), 12 TB cases) were compared with 27 age, gender, socio-economic and HIV status-matched patients, without history of respiratory diseases. Medical history and physical examinations were obtained every 6 months. Blood was drawn for CD4 and viral load measurements. A substantial number of HIV+ smokers who developed PCP (one-third) had been on highly active retroviral therapy (HAART) for more than 6 months and prophylaxis had been discontinued. Multivariate analyses indicated that in HIV-infected people, after controlling for HIV status and antiretrovirals, cigarette smoking doubled the risk for developing PCP (p = 0.01). Multivariate analyses demonstrated that long-term smoking also increased the risk (2 x) of developing tuberculosis (p = 0.04). Moreover, daily tobacco use seemed to attenuate by 40% the immune and virological response to antiretroviral therapies. These findings indicate that tobacco use significantly increases the risk of pulmonary diseases in HIV infected subjects and has a potential deleterious impact on antiretroviral treatment.

UR - http://www.scopus.com/inward/record.url?scp=0037359699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037359699&partnerID=8YFLogxK

U2 - 10.1080/1355621031000069864

DO - 10.1080/1355621031000069864

M3 - Article

VL - 8

SP - 39

EP - 43

JO - Addiction Biology

JF - Addiction Biology

SN - 1355-6215

IS - 1

ER -